Related Experiment Video
Updated: Dec 14, 2025
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
The pHLIP system as a vehicle for microRNAs in the kidney
Verónica Miguel1, Carlos Rey1, José Luis Aceña2
1Programa de Procesos Fisiológicos y Patológicos, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, España.
Abstract:
MicroRNAs (miRNAs) are small endogenous RNAs that regulate gene expression through post-transcriptional repression of their target messenger RNAs. A study of changes in expression of certain miRNAs in the kidney has supplied evidence on their pathogenic role and therapeutic potential in nephrology. This review proposes a nanotechnology approach based on the binding of analogs or inhibitors of miRNAs formed by peptide nucleic acids (PNAs) to peptides with a transmembrane structure sensitive to a low pH, called pHLIPs (pH [low] insertion peptides). The review draws on the concept that an acidic pH in the microenvironment of the renal tubule may facilitate concentration and distribution of the pHLIP-PNA complex in this organ. In this context, we have demonstrated for the first time that targeted administration of miR-33 inhibitors with the pHLIP system effectively prevents the development of renal fibrosis, thus opening up this technology to new strategies for diagnosis and treatment of kidney diseases.
Insights
This study introduces a novel nanotechnology approach using peptide nucleic acids (PNAs) and pH-sensitive peptides (pHLIPs) to target kidney diseases. Targeted delivery of microRNA-33 inhibitors via this system effectively prevented renal fibrosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Nanotechnology
Background:
- MicroRNAs (miRNAs) are key regulators of gene expression.
- Altered miRNA expression in the kidney is linked to disease pathogenesis and therapeutic potential.
- Current therapeutic strategies for kidney diseases require innovative delivery systems.
Purpose of the Study:
- To propose and evaluate a nanotechnology-based approach for targeted miRNA inhibition in kidney diseases.
- To investigate the use of peptide nucleic acids (PNAs) conjugated with pH-sensitive peptides (pHLIPs) for renal delivery.
- To demonstrate the therapeutic efficacy of targeting miR-33 in preventing renal fibrosis.
Main Methods:
- Design of a pHLIP-PNA complex for pH-sensitive drug delivery.
- Utilizing the acidic microenvironment of renal tubules for targeted drug accumulation.
- Administration of miR-33 inhibitors conjugated to pHLIPs in a preclinical model of renal fibrosis.
Main Results:
- The pHLIP-PNA system demonstrated effective concentration and distribution in the kidney.
- Targeted delivery of miR-33 inhibitors successfully prevented the development of renal fibrosis.
- This approach shows promise for novel diagnostic and therapeutic strategies in nephrology.
Conclusions:
- Nanotechnology, specifically pHLIP-PNA conjugates, offers a viable strategy for targeted miRNA-based therapies in kidney diseases.
- The pH-sensitive nature of pHLIPs facilitates localized drug delivery within the renal tubules.
- This innovative system holds potential for advancing the treatment and diagnosis of various kidney disorders.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs